Protent Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 26-06-2024
- Paid Up Capital ₹ 5.00 M
as on 26-06-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 14.90 M
as on 26-06-2024
- Revenue 34395.00%
(FY 2022)
- Profit 97.79%
(FY 2022)
- Ebitda 94.47%
(FY 2022)
- Net Worth -0.16%
(FY 2022)
- Total Assets 101.97%
(FY 2022)
About Protent Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.49 Cr.
Rahulkumar Tiwari, Dinesh Kumar, and Devopum Mishra serve as directors at the Company.
- CIN/LLPIN
U24100UP2019PTC114348
- Company No.
114348
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Mar 2019
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Protent Pharma Private Limited offer?
Protent Pharma Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops.
Who are the key members and board of directors at Protent Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahulkumar Tiwari  | Director | 31-May-2022 | Current |
| Dinesh Kumar | Director | 05-Mar-2019 | Current |
| Devopum Mishra | Director | 05-Mar-2019 | Current |
Financial Performance and Corporate Structure Insights of Protent Pharma.
Protent Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 34395% increase. The company also saw a substantial improvement in profitability, with a 97.79% increase in profit. The company's net worth dipped by a decrease of 0.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Protent Pharma?
In 2021, Protent Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 21 Mar 2023 | ₹0.90 M | Open |
Sidbi Creation Date: 22 Dec 2020 | ₹1.40 Cr | Open |
How Many Employees Work at Protent Pharma?
Unlock and access historical data on people associated with Protent Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Protent Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Protent Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
